Lady sitting in a bubble reading a book

CREATE A NURTURING ENVIRONMENT
FOR SKIN TO RESTORE ITSELF

Acute wounds (burns, traumatic wounds, abrasions, post-operative wounds), chronic wounds (leg ulcers, pressure ulcers and diabetic foot ulcers) and Epidermolysis Bullosa*
The UrgoTul logoThe UrgoTul Ag logo

WHAT Is RGOTULT?

UrgoTul is a flexible, non-adherent contact layer featuring the TLC Restoring Matrix that when in contact with wound exudate forms a lipidocolloid gel on the surface of the wound. This gel provides a moist environment optimal for multiplication of key cells for wound healing.
With UrgoTul, fibroblasts migrate within the wound area, proliferate and synthesize the extracellular matrix to form granulation tissue, bringing the edges of the wound together.3
UrgoTul keeps its integrity over time, without drying out and ensuring atraumatic and pain-free dressing changes.7,8

WHAT DO PATIENTS HAVE TO SAY?

UrgoTul was associated with no or less pain at dressing change4
UrgoTul graph showing almost no pain on dressing removal of acute woundsUrgoTul graph showing almost no pain on dressing removal of chronic wounds
Acceptability of TLC dressing (UrgoTul)9
Graph showing UrgoTul's positive attributes with patients

URGOTULTrange is clinically proven in more than 11,600 patients10

One-year old child presenting with a partial-thickness burn on the inside of the arm; after 15 days of treatment with UrgoTul, the wound has fully epithelialised11

Small child wound before using UrgoTulSmall child wound before after using UrgoTul

A 13-month-old child presenting with a traumatic wound on the forehead following a road traffic accident; after 7 days the wound has healed11

Small child with head wound before using UrgoTulSmall child with head wound after using UrgoTul
See clinical data in the UrgoTul brochure:
UrgoTul Brochure mockup
UrgoTul Ag Logo large

the jellIfYing silver contact layer proven to facilitate wound progress

Patients with light to moderately exudative partial and full thickness wounds, including diabetic ulcers, first and second degree burns, decubitus ulcers, venous stasis ulcers, and graft and donor sites
UrgoTul Ag interface with TLC description
See clinical data in the UrgoTul brochure:
UrgoTul Ag brochure mockup

Product information

Small UrgoTul logoUrgoTul product information about cutting
Size (inch)
Size (cm)
No. per box
Code
2 x 2
5 x 5
10
506487
4 x 5
10 x 12
10
506488
6 x 8
15 x 20
10
506489
4 x 16
10 x 40
10
603281
8 x 12
20 x 30
5
603283
UrgoTul Ag logo smallUrgoTul product information about cutting
Size (inch)
Size (cm)
No. per box
Code
4 x 5
10 x 12
10
509341
6 x 8
15 x 20
10
509342
8 x 16
20 x 40
5
553228

Clinical Support

For more in-depth information about the UrgoTul and UrgoTul Ag difference, please see the following resources and product brochures.

UrgoTul BrochureUrgoTul Ag BrochureUrgoTul ReviewUrgoTul Ag ReviewUrgoTul SDSUrgoTul Ag SDS

References

1. Meaume S. Urgotul®: a novel non-adherent lipidocolloid dressing. British Journal of Nursing. 2002, Vol 11, N°16. 2. Bernard FX et al. Effects of a lipidocolloid dressing on the production of the extracellular matrix. Journal des Plaies et Cicatrisations, 2007 (study conducted on Urgotul). 3. Bernard FX et al. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloïd dressing. Journal of Wound Care, May 2005; 14 (5): 215-220 (study conducted on Urgotul). 4. Meaume S et al. The importance of pain reduction through dressing selection in routine wound management: the MAPP study. J Wound Care. 2004;13(10):409-13. 5. Study report No. S/2003-007/BIOalternatives. 6. FX. Bernard et al., Effects of dressings on cellular proliferation and evaluation of their adherence to fibroblasts by in vitro culture. Oral communication, CPC 2005 7. M. Le Berre, Y. Lurton et al., Coated dressings: gauzes/contact layers. Poster, CPC 2005, Paris. 8. M. Le Berre, Y. Lurton et al., Coated dressings: gauzes/contact layers. Oral communication, CPC 2005, Paris. 9. Benbow M., Iosson, G. A clinical evaluation of UrgoTul to treat acute and chronic wounds. Br J Nurs 2004; 13: 2, 105–109. 10. White, R., Cowan, T., Glover, D. Supporting evidence-based practice: review of TLC healing matrix (2nd edition). MA Healthcare Ltd, London, 2015. 11. A. Le Touze et al., Interest of a new dressing (UrgoTul) in the management of wounds in a pediatric setting: results from a european clinical study. Poster, CPC 2005, Paris.
‍
Prior to use, be sure and read the entire Instructions for Use package insert supplied with the product for Device Intended Use, Description, Contraindications, Warnings, Precautions, Adverse Events, and Instructions for Use.

1.UrgoTul Ag data on file. 2. Lazareth I., Meaume S., Sigal-Grinberg M-L, et al. The Role of a Silver Releasing Lipido-colloid Contact Layer in Venous Leg Ulcers Presenting Inflammatory Signs Suggesting Heavy Bacterial Colonization: Results of a Randomized Controlled Study. WOUNDS 2008;20(6):158–166.
‍
Prior to use, be sure and read the entire Instructions for Use package insert supplied with the product for Device Intended Use, Description, Contraindications, Warnings, Precautions, Adverse Events, and Instructions for Use. Caution: Federal laws restrict this device to sale or on the order of a physican or licensed healthcare professional.

Page updated on 03 November, 2024
Copyright © 2024 Urgo Medical North America. All Rights Reserved.
‍
Privacy StatementPolicies & Guidelines